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Background: Intestinal mucositis is one of the major troublesome side effects of anticancer chemotherapy leading
to poor patient compliance. In this study we addressed the role of the novel apolipoprotein E (ApoE) COG 133
mimetic peptide in 5-fluorouracil (5-FU)-challenged Swiss mice and IEC-6 cell monolayers. Experiments were also
conducted in C57BL6J ApoE knock-out mice to assess the effects of apoE peptide treatment.
Methods: Experimental groups were as follows: unchallenged controls, 5-FU-challenged mice (450 mg/kg, i.p)
with or without the ApoE peptide (0.3, 1, and 3 μM, given twice daily i.p. for 4 days). Mice were sacrificed 3 days
after 5-FU challenge. Proximal small intestinal samples were harvested for molecular biology and histological
processing. We conducted ELISA assays and RT-PCR to target IL-1β, TNF-α, IL-10, iNOS, and myeloperoxidase (MPO)
to assess intestinal inflammation. Cell death and NF-κB assays were also conducted in apoE knock-out mice. In our
in vitro models, IEC-6 cells were exposed to 1 mM of 5-FU in glutamine free media with or without the ApoE
peptide (0.02, 0.2, 2, 5, 10, and 20 μM). We investigated IEC-6 cell proliferation and migration, 24 h after the 5-FU
challenge. Additionally, apoptotic IEC-6 cells were measured by Tunel and flow cytometry. Equimolar doses of the
ApoA-I (D4-F) peptide were also used in some experiments for comparative studies.
Results: Villus blunting and heavy inflammatory infiltrates were seen in the 5-FU-challenged group, findings that
were partially ameliorated by the ApoE peptide. We found increased intestinal MPO and pro-inflammatory IL-1β and
TNF-α levels, and TNF-α and iNOS transcripts, and reduction of IL-10 following 5-FU treatment, each of which were
partially abrogated by the peptide. Improvements were also found in IEC-6 cell apoptosis and migration following
ApoE and D-4F treatment.
Conclusion: Altogether, these findings suggest that the novel ApoE COG 133 mimetic peptide can reduce 5-FU-
induced intestinal changes and potentially benefit mucositis.
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The intestinal barrier function is very susceptible to injury
caused by anticancer drugs due to its rapid epithelial turn-
over rate of about 3–4 days [1]. Mucositis is a side effect
of chemotherapy in which there is a dramatic drop in
quality of life of patients, sometimes leading to discon-
tinuation of therapy. Chemotherapy cytotoxic effects vary
in severity according to therapy schemes and patient sus-
ceptibility, many of them may lead to intestinal mucosal
damage, heavy inflammatory responses, often associated
with increased epithelial cell death, intestinal epithelial
breakdown, and luminal bacterial translocation [2,3].
5-Fluorouracil (5-FU) is widely used for colorectal
cancer [4], but enteric inflammation accompanied by
diarrhea is a commonly reported side-effect. Intestinal
mucositis with diarrhea and vomiting is often the dose-
limiting adverse effect of 5-FU therapy and is likely
accompanied by poor treatment compliance.
Previous studies have demonstrated that 5-FU-treated
rats show significant reductions in villus height in the
upper small bowel, with increased epithelial cell damage,
increased leukocyte infiltrates and pro-inflammatory cyto-
kines in the intestinal mucosa [5]. In addition, our previ-
ous work found beneficial effects of alanyl-glutamine and
glutamine in reducing mucositis and accelerating mucosal
healing, following 5-FU challenge in Swiss mice [6]. In
vitro studies with IEC-6 monolayers exposed to 5-FU and
under glutamine supplementation also confirmed a pro-
mitotic activity of these gut-trophic nutrients [7].
Recently, a novel apolipoprotein E (ApoE) COG 133
mimetic peptide, comprising residues 133–149 of the
human apolipoprotein E has been reported [8]. This
mimetic peptide competes with the ApoE holoprotein for
binding the LDL receptor, with potent anti-inflammatory
properties in models of brain injury, yet preserving the
neuroprotective role of the holoprotein [9,10].
Investigators have found consistent anti-inflammatory
actions of a variety of ApoE mimetic peptides, with reduc-
tions in several pro-inflammatory cytokines and less activa-
tion of NF-κB [8,11]. In addition, ApoE mimetic peptides
have been found to inhibit NF-κB signaling in a model of
colitis supporting a role of this peptide in the intestinal
tract [12]. In the present study we investigated whether an
anti-inflammatory role of the ApoE COG 133 peptide
could improve the 5-FU-induced epithelial damage
assessed in Swiss mice and whether it could enhance epi-
thelial healing using in vitro monolayers of undifferentiated
crypt-derived IEC-6 cells. In addition, to assess whether the
ApoE COG 133 peptide could reverse the mucosal dam-
age-induced by the 5-FU challenge in the absence of the
endogenous protein, we also conducted experiments with
ApoE knock-out mice and their wild-type controls. To our
knowledge this is the first study addressing the role of the
apopoliprotein E in 5-FU-induced intestinal mucositis.Methods
In vivo studies
Drugs
5-fluorouracil (Eurofarma, SP, Brazil) was obtained from
the Laboratory of Inflammation and Cancer (LAFICA)/
Federal University of Ceara for the intestinal mucositis
induction. The ApoE COG133 and apoA-1 (D-4F) peptide
were provided by Dr. Michael Vitek at Duke University
(Durham, North Carolina, USA). The ApoE COG 133 and
apoA-I (D-4F) peptides were synthesized from the Peptide
Synthesis Laboratory at the University of North Carolina
(Chapel Hill, NC) to a purity of 95% and reconstituted in
sterile isotonic PBS. The ApoE COG 133 amino terminus
was acetylated, and the carboxyl terminus was blocked
with an amide moiety. The 17-amino acid peptide was
derived from ApoE residues 133–149 (the receptor
binding region): Ac-LRVRLASHLRKLRKRLL-amide. The
lyophilized peptides (ApoE COG 133 and D-4F) were
diluted in distilled water and saved frozen as stock solution
and aliquot to prepare experimental doses.
Animals
Swiss and C57BL6J ApoE wild-type and knock-out mice
(weighing between 25 and 30 g) were obtained from the
Department of Physiology and Pharmacology vivarium,
Federal University of Ceará. All experimental protocols
were in compliance with the Brazilian College for
Animal Experimentation (COBEA) and the Animal Care
and Use Committee guidelines from the Federal University
of Ceará. Experimental mice were kept in polyethylene
boxes with free access to chow diet and water until
sacrifice, and subjected to 12 h light–dark cycles.
Mucositis induction, ApoE treatment and tissue collection
Intestinal mucositis was induced by single 5-fluorouracil
administration (450 mg/kg) intraperitoneally (i.p) in
Swiss and ApoE wild-type and knock-out mice, which
was considered as day 1st. ApoE COG 133 peptide was
given daily (12/12 h, i.p. 0.3, 1.0 and 3.0 μM) during the
1st to 4th days following the 5-FU challenge. Animals
were weighed daily. The euthanasia was performed on
the 4th day in anesthetized mice with an overdose of
ketamine/xylazine solution. After sacrifice, 1 cm-long
segments of the proximal small intestine were harvested
and immediately frozen in liquid nitrogen and thereafter
stored in −80°C freezer until use. Each first 1-cm long
segment after the pyloric valve was picked and stored in
buffered formaldehyde solution for further histology
processing.
Leukocyte counts
In order to evaluate the 5-FU myelocytotoxicity,
leukocyte counting was performed using Newbauer
chambers. Swiss mice were slightly anesthetized with
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plexus to draw peripheral blood, which was mixed with a
3% acetic acid solution (Turk’s solution) at a 1:20 ratio
for loading. Final counts were given as the number of
cells per mm3.
Villus height and crypt mitotic index
In order to evaluate the role of ApoE COG 133 in healing
the injured intestinal mucosa, we measured villus height in
at least 10 villus longitudinal sections using low-magnified
H&E-stained photomicrographs by Image J software 1.4 W
(NIH - National Institutes of Health, Bethesda, MD, USA)
after proper calibration. Villus height was measured from
the base-apex longitudinal axis. In order to find whether
the ApoE COG 133 peptide restores epithelial cell renewal
in ApoE knock-out mice, the mitotic index was also
calculated in these mouse strains by blindly counting well-
defined mitotic figures at the crypt proliferative compart-
ment, as described elsewhere [6]. Measures were done
under light microscopy using an immersion objective
(1000X). The absolute values were averaged to produce
the mitotic index of each group.
Inflammation markers
Myeloperoxidase (MPO) assay MPO tissue activity is
used as a marker of inflammatory cell infiltrates (espe-
cially neutrophils) in the inflamed tissue [13]. Segments
from the proximal small intestine were incubated in
0.5% HTAB (hexadecyltrimethylammonium bromide)
solution at a ratio of 50 mg of tissue/ml of buffer, and
homogenized and centrifuged (1500G/15 min at 4°C).
The supernatant was transferred to an Epperdorf tube
and further centrifuged (10 min). After plating of the
supernatant (7μL onto a 96- plate well), 200 μL of the
reading solution (5 mg of O-dianisidine, 15 μl of 1%
H2O2, 3 ml of phosphate buffer and 27 ml of H2O) were
added and read at 450 nm (t0 = 0 min and t1 = 1 min).
The change in absorbance was obtained and expressed
as MPO/mg tissue (MPO activity).
ELISA cytokine assay
Specimens were stored at −80°C until required for assay.
The tissue collected was homogenized and processed
as described by Soares et al [14]. The detection of TNF-α,
IL-1β, and IL-10 concentrations was determined by ELISA.
Briefly, microtiter plates were coated overnight at 4°C with
antibody against murine TNF-α, IL-1β, and IL-10 (2 μg/
ml). After blocking the plates, the samples and standard at
various dilutions were added in duplicate and incubated at
4°C for 2 h. The plates were washed three times with buf-
fer. After washing the plates, biotinylated sheep poly-
clonal anti-TNF-α or anti-IL-1β or anti-IL-10 (diluted
1:1000 with assay buffer 1% BSA) was added to thewells. After further incubation at room temperature
for 1 h, the plates were washed and 50 μl of avidin-HRP
diluted 1:5000 were added. The color reagent o-phenylene-
diamine (OPD; 50 μl) was added 15 min later and the plates
were incubated in the dark at 37°C for 15–20 min. The en-
zyme reaction was stopped with 2 N H2SO4 and absorbance
was measured at 490 nm. Values were expressed as pico-
grams/milliliter (pg/ml).
Reverse transcriptase-PCR
Based on our previous results, described above, we chose
the 3 μM, as the best ApoE mimetic peptide dose for the
RT-PCR studies. Briefly, proximal intestinal samples were
immediately immersed and frozen in liquid nitrogen and
stored at −80°C until immediately before analyses. Samples
were thawed and resuspended in a denaturating solution
(4 M guanidinium thiocyanate, 25 mM sodium citrate, pH
7, 0.5% sarcosyl) and extracted using RNeasy mini columns,
according to manufacturer’s instructions (RNeasy mini kit,
Qiagen, Valencia, California). Total RNA was quantified
and checked for purity (A260:280 ratio) by standard
spectrophotometry (Biophotometer, Eppendorf, Hamburg,
Germany). First strand of cDNA was synthesized from 2 μg
of total RNA using oligo(dT)12-18 as primers in the
presence of Moloney murine leukemia virus reverse tran-
scriptase (Superscript™ Reverse Transcriptase, Invitrogen,
Carlsbad, California), for 1 hr at 37 C. PCR was carried out
with 5 μl of the RT-product (50 μl final reaction volume)
with 5 μl of reverse and forward murine primers (Invitro-
gen) for TNF-α and iNOS. Primers were according to
Coutinho et al, 2010 [15].
Amplicons were generated in thermal cycler (Biorad,
Hercules, CA) conditions. The temperature profile of the
amplification consisted of 35 cycles of 45 s denaturation at
95 C and 2.5 min annealing and extension at 60 C.
Negative controls were without RNA. PCR products were
separated onto 2% agarose gel and visualized by ethidium
bromide staining and photographed digitally using a gel
documentation system (Alpha Imager, Alpha Innotech
Corp., San Leandro, California). The housekeeping gene,
β-actin, was used as an internal control. Sample band
densities were ratio-normalized by using β-actin band
intensities, obtained within the same PCR reaction, with the
aid of NIH Image J software (NIH, Bethesda, Maryland).
NF-κB immunohistochemistry
Immunohistochemistry for NF-κB p50 (NLS) was
performed on proximal intestine tissue from ApoE
knock-out mice and wild-type controls using the
streptavidin-biotin-peroxidase method in formalin-fixed,
paraffin-embedded tissue sections (4μm thick), mounted
on poly-L-lysine-coated microscope slides. The sections
were deparaffinized and rehydrated through xylene and
graded alcohols. After antigen retrieval, endogenous
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hydrogen peroxide and washed in phosphate-buffered
saline (PBS). Sections were incubated overnight (4°C)
with primary rabbit anti-NF-κB antibody diluted 1:200 in
PBS plus bovine serum albumin (PBS-BSA). The slides
were then incubated with biotinylated goat anti-rabbit;
diluted 1:400 in PBS-BSA. After washing, the slides were
incubated with avidin-biotin-horseradish peroxidase
conjugate (Strep ABC complex by VectastainW ABC
Reagent and peroxidase substrate solution) for 30 min,
according to the Vectastain protocol. NF-κB was visualized
with the chromogen 3,3′diaminobenzidine (DAB).
Negative control sections were processed simultaneously
as described above but with the first antibody being
replaced by PBS-BSA 5%. None of the negative controls
showed NF-κB immunoreactivity. Slides were counter-
stained with Harry’s hematoxylin, dehydrated in a graded
alcohol series, cleared in xylene and coverslipped.
Apoptotic assay
In order to find whether the ApoE COG 133 peptide
could restore cell viability in ApoE knock-out mice, we
also performed a Tunel assay. The fragmentation of
DNA was examined using a commercial kit for the
detection of apoptosis (ApopTagW Plus Flourescein in
situ Apoptosis Dectection kit, Chemicon, Temecula, CA,
USA) using the Tunel technique. After deparaffinization
and hydration, sections were subjected to enzymatic
digestion with 20 μg/mL of proteinase K for 15 min,
washed with phosphate-buffered saline (PBS), 0.1 M, pH
7.4. They were then immersed in an equilibration buffer
for 10 min and incubated with a stock solution of
terminal deoxynucleotidyl transferase enzyme at 37C for
1 h. They were then washed with PBS and incubated
with antidigoxygenin-fluorescein conjugate for 30 min in
the dark using a humidified chamber. Apoptotic figures
were then visualized using a confocal laser scanning
microscope (FV100, Olympus, USA). Tunel-labeled cells
were counted and averaged as total labeled cells per high
magnification field, according to experimental groups.
In vitro studies
Cell culture
Rat crypt jejunal cells (IEC-6) were cultured at 37°C in a
5% CO2 incubator. The maintenance cell media used
was Dulbecco’s Modified Eagle Media (DMEM; Gibco
BRL, Grand Island, NY) supplemented with 5% fetal calf
serum (FCS), 5 mg bovine insulin, 50 μg/ml of penicillin/
streptomycin (DMEM; Gibco BRL, Grand Island, NY)
and a final concentration of 1 mM of sodium pyruvate.
The media were changed thrice a week, according to
standard culture protocols. Dulbecco’s Modified Eagle
Medium without Gln (DMEM; Gibco BRL) was used
whenever the supplementation effect of the ApoE novelpeptide was evaluated. We tested the effect of the
COG133 peptide (ApoE 133) and D-4F peptide (ApoA-I)
at 0.02, 0.2, 2, 5, 10, and 20 μg/ml. The D4-F peptide
was chosen since it has been found as anti-inflammatory
action in models of cardiovascular disease [16]. Both
peptides were supplied as a lyophilized powder and
reconstituted in sterile water and aliquot into smaller
sample sizes for dosing experiments in sterile lactated
ringers stored at −80°C.
Wound Healing Assay
For wounding assay, we used rat jejunal epithelial cells,
IEC-6 cells (passage 19). IEC-6 cells were seeded in 6
well plates at a concentration of 106 cells per well and
were allowed to grow until full confluence, before
wounding cells were challenged with 1 mM of 5-FU.
After 1 hour of treatment with 5-FU, cells were washed
twice with 1xPBS and scratched with a sterile razor blade
at the midline extending to the right side of the well.
The intention of the scrape is to simulate epithelial
damage and measure cell migration from the injured site
during the early phase of tissue recovery. After wounding,
the wells were washed again, two times with 1xPBS and the
media were changed to glutamine-free media containing
different concentrations (0.02; 0.2; 2.0; 5.0; 10, and 20. μM)
of mimetic peptides ApoE COG133 and D4F. Migrated
cells were observed under 10X magnification after 24 h
using Olympus Inverted microscope with QImaging
camera. Areas of the farthest cell migration were chosen,
and images were taken using QCapture Pro.5.1.software.
Cells were manually counted and expressed as number of
cells per mm2.
Cell proliferation assays
WST assay Cell proliferation was measured indirectly
using the tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2 H-
5-tetrazolio]-1-3-benzene disulfonate), according to the
manufacturer’s recommendations. A 96-well plate was
seeded with IEC-6 cells in a total concentration of 4 x 104
cells/mL in 100μL of standard DMEM media. Cells
were allowed to attach for 48 h, when the media volume
was removed and changed to standard medium (SM)
(0.01–100nM) or not, and then either incubated or not with
5-FU (1 mM) for 1 hour. After 24 h and 48 h, wells were
incubated for 2 h with 10 mL of the tetrazolium salt and
the absorbance was measured using an ELISA microplate
reader at 450 nm (reference range 420–480 nm). Tetrazo-
lium salts are cleaved to formazan by mitochondrial
enzymes in viable cells. Enhancement of the number of
viable cells will result in an increase of the amount of the
formazan dye, which is detectable by the ELISA reader.
Therefore, this model indirectly measures the cell prolifera-
tion rate in a time dependent manner.
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IEC-6 cells were plated in 2-well tissue culture chamber
slides at a concentration of 105 cells per well. Cells were
allowed to attach the chamber slide for 24 hours. After
24 hours, cells were challenged for 1 hour with 5-FU
(1 mM), then washed twice with 1xPBS and treated with
either ApoE COG133 or apoA-I D4F mimetic peptides
in two different concentrations: 2. and 20μM. Cells
were then exposed to mimetic peptides for 6 hours in
glutamine-free medium. After the treatment cells were
washed trice with 1xPBS and fixed in 4% paraformalde-
hyde (methanol free) for 15 minutes, then washed trice
with 1xPBS. IEC-6 cells were stained by using Ki67
antibody (MKI67rabbit monoclonal primary antibody)
from Epitomics Inc. (Burlingame,CA). Ki67 is a nuclear
protein that is tightly linked to the cell cycle and lables
cell proliferation. Working dilution of primary antibody
was 1:400. Secondary antibody used was anti-rabbit from
DAKO, (Carpinteria, CA). Staining was done in Tissue
Research Core Facility at University of Virginia Medical
School. Images were taken in the Core Facility using
Olympus DP71 microscope and Microsuite Pathology
Edition software using ×20 magnifications with a 100 μm
scale. We evaluated 6 to 8 randomly selected areas. Ki67
positive cells were counted manually and calculated per
total number of cells, expressed as percentage of Ki67
positive cells.
Cell death assays
Tunnel IEC-6 cell were plated in 2-well tissue culture
chamber slides at a concentration of 105 cells per well.
Cells were allowed to attach the chamberslide for 24
hours. After 24 hours cells were challenged for 1 hour
with 1 mM 5-FU, then washed twice with 1 × PBS and
treated with APOE COG133 and APOA-I D4F mimetic
peptides in 6 different concentrations: 0.02; 0.2; 2.0; 5.0;
10, and 20μM. Cells were then exposed to mimetic
peptides for 24 hours in glutamine-free medium. After the
treatment cells were washed trice with 1×PBS and fixed
in 4% paraformaldehyde (methanol free) for 15 minutes,
then washed trice with 1×PBS. Cells were stained with
using DeadEnd Fluorometric Tunel kit from (Promega,
Madison, WI). Tunel System measures the fragmented
DNA of apoptotic cells by catalytically incorporating
fluorescein-12-dUTP at 3′-OH DNA ends using the
enzyme TdT (Terminal deoxynucleotidyl Transferase).
Apoptotic cells were visualized using DAPI (SouthernBio-
tech., Birmingham, AL). Images were taken under 10× and
×40 magnification using Fluorescent Olympus 1 ×71
Inverted microscope with QImaging camera, with QCap-
ture Pro.5.1.software. We evaluated 10 randomly selected
fields. Cells were manually counted per selected area and
expressed in number of cells per mm2.Flow cytometry
Apoptosis and necrosis were measured using the ApoAlert
Annexin V kit. Annexin V is a molecule that binds to
phosphatidylserine (PS) and, when conjugated to a fluoro-
chrome, detects apoptotic cells expressing PS on the
reversed membrane surface. For this protocol, propidium
iodide (PI) was also used to detect necrotic and late
apoptotic cells, which express PI inside the membrane.
The cells were seeded on 12-well plates at a concentration
of 5 × 105 cells/well. These cells were allowed to attach to
the plate surface for 24 h. Afterwards, cells were washed
with DMEM Gln-free media and either incubated or not
with 5-fluorouracil for 1 h. Wells were then washed again
and supplemented with COG133 and then incubated for
24 h. Cells were trypsinized, centrifuged, and washed with
serum containing media, before incubation with Annexin
V. Cells were counted and diluted to 105–106 cells and
were rinsed and resuspended in 200 μl of binding buffer.
Five microliters of Annexin V and 10 μl of PI were added
and incubated for 5–15 min in the dark. The samples wer-
e then processed at the University of Virginia’s Flow
Cytometry Core, using a Calibur (Becton Dickinson)
dual laser fluorescence-activated cell sorter (FACS). Low-
concentrated bovine fetal serum was used to further
evaluate peptide treatment under deprived media.
Statistical analysis
The results are shown as mean ± SEM. Either analysis of
variance ANOVA followed by Student Newman-Keuls
for multiple group comparisons or Student’s T test
for unpaired comparisons between two groups were
used. P <0.05 was set to indicate significant differences.
Results
In vivo studies
Weight gain and leukocyte counts
As expected, 5-FU-injected mice (450 mg/Kg, i.p) (day of
injection = day 1) show profound weight loss compared
with the unchallenged controls from the 3rd day post-
challenge (two days after 5-FU injection) (p< 0.001).
ApoE COG 133 mimetic peptide treatment (0.3, 1 and
3 μM) did not improve weight loss caused by the high 5-
FU dose used in our protocols in either Swiss mice or
ApoE knock-out mice. 5-FU-challenged mice exhibited
marked reductions (77.1%) in the leukocyte count (cell
number/mm3 from peripheral blood), compared to the
unchallenged control group (p< 0.001), confirming that
the 5-FU-tested dose was cytotoxic to the bone marrow,
and this effect was also not diminished by the ApoE
COG 133 peptide administration (p> 0.05, by ANOVA),
although a trend of increased leukocyte counts was
seen. Nevertheless, when a group-by-group comparison
between the 5-FU controls and the highest doses of the
peptide was made, a significant improvement in the
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by unpaired Student T test) (data not shown).
Histology
In our protocol, the 5-FU-induced intestinal mucositis
features a heavy inflammatory response, with increased
inflammatory cell infiltrates in the submucosa and
mucosa, mostly invading polymorphonuclear leukocytes.
In addition, profound villous atrophy, with villus blunting
and crypt derangement are seen, as opposed to the unchal-
lenged control (Figure 1). The ApoE mimetic peptide
improved intestinal inflammation cell infiltrates and villus
height (doses of 1 and 3 μM, p <0.001), as compared with
the untreated challenge mice (Figure 1A). Since, the dose
of 3 μM was beneficial to 5-FU-treated Swiss mice, we also
tested this dose in the experiments conducted with the
ApoE knock-out mice. ApoE COG mimetic peptide
(3 μM) was also able to improve the duodenal histology
following 5-FU treatment in ApoE deficient and wild-type
mice, with significant improvements in villus height
(Figure 1B).
5-FU-treated mice show profound cell proliferation im-
pairment, as demonstrated by ablated mitotic index in the
duodenal crypts. The ApoE COG 133 peptide at 3 μM
significantly increased the mitotic crypt numbers in
C57BL6J wild-type animals but not in ApoE knock-out
mice. In addition, COG 133 treatment improved crypt
architecture and reduced lamina propria inflammation,
compared to untreated controls (Figure 2).
Myeloperoxidase (MPO) and ELISA cytokine assays
We found increased intestinal myeloperoxidase levels
(an enzyme found in neutrophil azurophilic granules),
following 5-FU administration. ApoE COG 133 peptide
caused a significant reduction in the intestinal MPO
levels at the maximum dose tested (3 μM) (p <0.05)
(Figure 3A). Additionally, we found increased intestinal
IL-1β levels following 5-FU treatment, an effect that was
partially abrogated by the ApoE peptide administration
at doses of 1 and 3 μM (p< 0.05 and p< 0.001, respect-
ively), Figure 3B.
As seen in Figure 3C, we also found increased TNF-α
levels in the proximal small intestine from 5-FU-treated
mice, which were partially decreased after ApoE COG
133 peptide administration in all doses tested (p <0.001).
On the other hand, 5-FU administration caused mark-
edly reduced intestinal IL-10 levels, effects that were
again improved with ApoE peptide treatment (at highest
dose) (p< 0.001) (Figure 3D).
Reverse Transcriptase-PCR
Our findings have shown increased intestinal TNF-α pri-
mary transcripts following 5-FU challenge, as compared
to the controls (p <0.001), which was significantlyreduced by the ApoE COG 133 peptide (3 μM). In
addition, inducible nitric oxide synthase (iNOS) tran-
scripts were increased in the proximal intestine after
5-FU challenge, as well. Likewise, the ApoE peptide
treatment reduced iNOS mRNA expression (Figure 4).Apoptosis detection by TUNEL assay
Mice treated with 5-FU (450 mg/kg i.p.) showed a signifi-
cant increase in Tunel-positive cells in the proximal
intestine, an effect that was reverted by COG 133 adminis-
tration (3 μM) in both wild-type and ApoE knock-out mice
(Figure 5A). As expected, 5-FU treatment caused marked
NF-κB immunolabeling of mucosa in wild-type mice.
Interestingly, 5-FU-ApoE knock-out mice showed less
intense NF-κB immunostaining as compared with their
wild-type counterparts. In addition, the COG 133 treatment
caused even higher expression of the NF-κB in the
improved intestinal mucosa. NF-κB heavier labeling was
associated with recovered crypt and villus epithelia
(Figure 5B).In vitro studies
Proliferation assays
IEC-6 monolayers challenged with 5-FU (1 mM for 1 h
diluted in standard glutamine- containing media) showed
reductions in cell numbers (lower mitochondrial activity,
as measured by formazan detection) 24 h after 5-FU as
compared to unexposed IEC-6 cells in glutamine
enriched media (p< 0.001), suggesting that 5-FU
increased glutamine uptake during 5-FU challenge. ApoE
peptide treatment was not able to improve cell numbers
in glutamine enriched media following 5-FU exposure in
any of the doses tested. In fact, the highest dose of
20 μM caused significant cell proliferation impairments
as compared to 5-FU controls (Figure 6A).
5-FU pre-treated IEC-6 monolayers showed reduced
cell numbers, as compared with monolayers seeded in
glutamine free-medium (p = 0.05). The ApoE peptide,
at doses of 0.02, 0.2, and 2.0 μM, improved cell
numbers in glutamine free media, suggesting a greater
effect during a catabolic stress (Figure 6B). In order to
measure mitotic activity we used Ki67 immunolabeling
to further confirm the proliferative effect of COG 133.
5-FU-challenged monolayers showed lower Ki67
labeling (% of positive cells in higher magnified field).
We found no improvement in Ki67 immunolabeling
with either 2 or 20 μM COG 133. However we found
increased numbers of cells showing and areas of
clustering suggesting a proliferative nest. In order to
evaluate the HDL receptor involvement, we have used
D-4F, with significant improvements only at the
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Figure 1 A. Representative histology and villus height from H-E stained-proximal intestine (X100) of Swiss mice challenged by 5-FU-
induced intestinal mucositis (450 mg/kg via i.p., single dose, and treated with the apoE mimetic peptide COG 133 (0.3, 1, and 3 μM, via
i.p., 12/12 h, vol. 10 μl/g) or 0.9% saline (i.p.). Scale bar = 100 μm. B. Representative histology and villus height from H-E stained-proximal
intestine (X100) of C57BL6J ApoE knock-out and wild-type mice challenged by 5-FU-induced intestinal mucositis (450 mg/kg via i.p., single dose)
and treated with the apoE mimetic peptide COG 133 (3 μM, via i.p., 12/12 h, vol. 10 μl/g) or 0.9% saline (i.p.). Scale bar = 100 μm. The arrow
indicates a heavy inflammatory cell infiltrate in the submucosal tissue from the 5-FU-treated mice. Note reductions of inflamed tissue in apoE COG
133-treated groups, especially in the highest doses. Values represent mean ± SEM and were analyzed by one-way ANOVA and Bonferroni. At least
10 villi per animal were analyzed (n = 4 animals/group). Experimental mice were sacrificed on the fourth day post-challenge.
































Figure 2 Mean mitotic index of the H&E stained-duodenal crypts (X1000) from C57BL6J ApoE knock-out and wild-type mice challenged
by 5-FU-induced intestinal mucositis (450 mg/kg via i.p., single dose) and treated with the apoE mimetic peptide COG 133 (3 μM, via i.p.,
12/12 h, vol. 10 μl/g) or 0.9% saline (i.p.). Values represent mean ± SEM and were analyzed by one-way ANOVA and Bonferroni. At least 10
crypts per animal were analyzed (n = 4 animals/group).Experimental mice were sacrificed on the fourth day post-challenge.
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5-FU (1 mM) markedly reduced IEC-6 cell migration in
glutamine-free media, as compared to the unchallenged
control (24 h post-challenge). COG 133 (0.2-20 μM)
improved cell migration following 5-FU challenge
(p = 0.0001), reaching the same migration level as con-
trols (Figure 7A and B). When D-4F was tested under
the same conditions, similar benefits were seen, however
not at its lowest dose (Figure 7C).Cell viability assays
Using Tunel labeling, we found increased apoptotic
figures (measured by % of apoptotic cells in total cell
population at high magnification) after 5-FU challenge in
glutamine free-media, effects that were ameliorated witheither ApoE COG 133 or the D-4F peptides at the same
doses (2–20 μM) (Figure 8A).
We also tested the ApoE mimetic peptide under low
bovine fetal serum concentrations with glutamine-free
medium (1%), a stress condition that significantly
reduces cell viability [17]. Triplicate flow cytometry
analyses demonstrated, as expected, a significant increase
in apoptosis in IEC-6 cells 24 h post-5-FU challenge. ApoE
peptide treatment reduced cell apoptosis in glutamine-free
media with low bovine fetal serum concentration
(p< 0.05). However, when necrotic cells were considered
for analysis, we found similar necrotic features in the
glutamine-deprived IEC-6 controls and 5-FU-challenged
cells (p> 0.05). In addition, ApoE peptide treatment did
not reduce necrotic cells compared to both 5-FU-exposed
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Figure 3 A. Proximal intestinal myeloperoxidase (MPO) assay from Swiss mice challenged by 5-FU-induced intestinal mucositis
(450 mg/kg via i.p., single dose) and treated with the apoE mimetic peptide COG 133 (0.3, 1, and 3 μM, via i.p., 12/12 h, vol. 10 μl/g) or
0.9% saline (i.p.). B, C, and D. IL-1β, TNF-α, and IL-10 Elisa assays, respectively, from Swiss mice challenged by 5-FU-induced intestinal mucositis
(450 mg/kg via i.p., single dose) and treated with the apoE mimetic peptide COG 133 (0.3, 1 and 3 μM, via i.p., 12/12 h, vol. 10 μl/g) or 0.9% saline
(i.p.). Proximal intestine segments were harvested from experimental mice on the fourth day. Values represent mean ± SEM and were analyzed by
one-way ANOVA. At least four animals were used per group. At least N = 7 for all groups.
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Figure 4 Reverse-transcriptase analyses on tumor necrosis factor-alpha (TNF-α) and inducible nitric oxide synthase (iNOS) mRNA
transcripts in the proximal intestine (N=4 for each group). Proximal intestinal segments were harvested from experimental mice on the
fourth day. Densitometry results after normalized by β-actin are shown as mean ± SEM.
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5-FU is one of the most prescribed drugs in clinical
oncology for colo-rectal cancer patients [18,19], however
side effects are often reported, leading to compliance
failure. The intestinal barrier function may suffer from5-FU cytotoxic insults in various ways, including
mucosal inflammatory reactions, intestinal epithelial
barrier disruption, and bacterial translocation [20].
The data described here are in accordance with previ-
ous work from Soares et al., who followed 5-FU-treated
AWild-type
ApoE Ko



































Figure 5 A. Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) analysis of apoptosis in C57BL6J apoE
knock-out and wild-type mice challenged by 5-FU-induced intestinal mucositis (450 mg/kg via i.p., single dose) and treated with the
apoE mimetic peptide COG 133 (3 μM, via i.p., 12/12 h, vol. 10 μl/g) or 0.9% saline (i.p.). Values represent mean ± SEM and were analyzed
by one-way ANOVA and Bonferroni.. TUNEL-labeled cells (head arrows) were found increased 5-FU treated mice. Effect that was reversed by ApoE
COG 133 peptide. Scale bars = 10 μm. B. NF-κB p50 representative immunohistochemistry of the proximal intestine tissue (X400) after four days of
5-FU-challenge. Note higher NF-κB immunlabeling in recovered crypts treated by ApoE COG 133 peptide. Scale bars, 10 μm.
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Figure 6 Dose response of the apoE COG 133 mimetic peptide (0.02-20 μM) on IEC-6 cell proliferation 24 h after 5-FU challenge (5-FU
media exposure for 1 h) in glutamine-free media (A) or standard media (B), detected by formazan absorbance using an ELISA
microplate reader at 450 nm in 96-well seeded IEC-6 cells. Values represent mean ± SEM and were analyzed by one-way ANOVA. (C) Ki67
immunolabeling of IEC-6 cells from chamber slides 24 h after 5-FU challenge (5-FU media exposure for 1 h) in glutamine-free media with
either ApoE (COG 133) or ApoA-I (D-4F) peptides. Squares show areas of nested cells, suggesting a cloning cluster. Values represent mean% of
Ki67-labeled cells in high magnified fields (X400) and were analyzed by one-way ANOVA.
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Figure 7 A. ApoE mimetic (COG 133) effect on IEC-6 cell migration, 24 h after 5-FU challenge (5-FU media exposure, 1 mM, for 1 h). Cell
proliferation was analyzed under glutamine-free media using WST assay. B. ApoA-I (D-4F) peptide (0.02-20 μM) effect on IEC-6 cell migration, 24 h
after 5-FU challenge (5-FU media exposure, 1 mM, for 1 h). Cell proliferation was analyzed under glutamine-free media using WST assay. Values
represent mean ± SEM and were analyzed by one-way ANOVA.
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Figure 8 A. Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) analysis of apoptosis in IEC-6 cells were
analyzed under 5% fetal bovine serum and exposed to 5-FU, with either ApoE (COG 133) or ApoA-I (D-4F) peptide treatment. Cells were
stained using DeadEnd Fluorometric Tunel kit (head arrows). The Tunel System measures the fragmented DNA of apoptotic cells by catalytically
incorporating fluorescein-12-dUTP at 3′-OH DNA ends using the enzyme TdT (Terminal deoxynucleotidyl Transferase). Data are plotted as mean
TUNEL-labeled cells under high magnification (X400). Values represent mean ± SEM and were analyzed by one-way ANOVA. B. Cell necrosis and
apoptosis were analyzed with flow cytometry in 1% fetal bovine serum and exposed to 5-FU with ApoE COG 133 peptide treatment. Cells were
stained with FITC-conjugated annexin V and propidium iodide and analyzed by flow Calibur dual laser fluorescence-activated cell sorter (FACS).
Results are shown as density plots with propidium iodide vs. annexin V-FITC. Bars on the graph represent the percentage of apoptotic cells have
apoptotic and necrotic cells.
Azevedo et al. BMC Gastroenterology 2012, 12:35 Page 14 of 18
http://www.biomedcentral.com/1471-230X/12/35
Azevedo et al. BMC Gastroenterology 2012, 12:35 Page 15 of 18
http://www.biomedcentral.com/1471-230X/12/35rats (1, 3, 5, 15 and 30 day) and showed marked
leukopenia, MPO activity, inflammatory cell infiltration,
villus shortening, and crypt destruction in the duodenal
lamina propria on the third day post-5-FU challenge [5].
Interestingly, we found a marked crypt mitotic arrest in
5-FU treated mice, which was ameliorated by COG 133
peptide only in wild-type but not ApoE knock-out mice, as
shown by our findings of crypt mitotic index. This may be
caused by a disrupted growth factor signaling, since we
had shown impaired intestinal adaptations during catch-
up growth following re-feeding in severe undernourished
ApoE knock-out mice, with poor intestinal IGF-1
expression [21].
Our data suggest that ApoE mimetic peptide may
modulate inflammation by increasing NF-κB expression
in recovered epithelia from duodenal crypts, therefore
may be also activating the NF-κB anti-inflammatory
pathway. NF-κB signaling has been found to improve
epithelial migration after intestinal injury [22], and has
been shown to be associated with cyclin 1 expression
[23], both factors that could improve crypt recovery from
5-FU epithelial damage. Although, COG 133 peptide
could also enhance intestinal mucosal repair in ApoE
knock-out mice, the NF-κB immunolabeling was less
increased than in the wild-type mice following ApoE-
peptide treatment. Further studies are warranted to
examine this effect in more depth, especially addressing
growth factors involved in mucosal restitution and their
regulation by ApoE peptides.
Recent studies in rats demonstrated that 5-FU admin-
istration (150 mg/kg i.p.) significantly increased MPO
activity (275%) in the jejunum, as compared with unchal-
lenged controls [24]. In addition, increased concentrations
of TNF-α and IL-1β with involvement of platelet-activating
factor were found in the rat duodenum [25]. In order
to assess inflammatory responses to 5-FU challenge, we
measured ileal cytokines and MPO levels. Our findings
also showed marked increases in intestinal MPO activity
on the 3rd day after 5-FU challenge (450 mg/kg i.p), effects
that were abrogated in mice treated with 3 μM COG133
peptide, suggesting a reduction of the MPO-producing
inflammatory cell infiltrates by the peptide.
In our study, we detected increased levels of IL-1β and
TNF-α and their transcripts (and reduced IL-10 levels)
and increased expression of the inflammatory mediator
iNOS mRNA in the proximal small intestine among 5-FU
challenged Swiss mice, findings that were partially
abrogated by ApoE mimetic peptide treatment, supporting
an anti-inflammatory role of the ApoE mimetic peptide in
the 5-FU-driven intestinal mucositis. This finding of ApoE
modulatory action on pro-inflammatory cytokines is
reinforced by reports of a pro-inflammatory state in mice
lacking the APOE gene [26] and poor survival of these
animals in models of sepsis [27]. Studies by Lynch andcolleagues have demonstrated an anti-inflammatory effect
of the ApoE peptide, COG 133, when administered intra-
peritoneally to LPS-challenged (i.p.) mice, leading to
significant reductions in serum TNF-α after 1 and 3 hours.
Such anti-inflammatory effect was also found in the brain
tissue of these mice, with reductions in the TNF-α mRNA
expression 3 hours after LPS injection [8]. Furthermore,
an anti-LPS role is also postulated in studies using human
recombinant ApoE. ApoE- enriched emulsion can shift
bacterial LPS from liver Kupffer cells to hepatocytes,
therefore reducing LPS-derived endotoxemia (binds at
ratio of 1:2 LPS molecules) [28,29]. These findings suggest
that the benefit of ApoE mimetic peptide we observed
may have been through blocking effects of bacterial (or
LPS) translocation following 5-FU-induced intestinal
barrier leakage.
Regarding mediators that might be altered by ApoE
mimetic peptides, TNF-α and IL-1β are important pro-
inflammatory cytokines activated by NF-κB pathway,
which is up-regulated during the pathogenesis of 5-FU-
induced mucositis [30] [31]. Interestingly, the ApoE
COG-112 mimetic peptide was found to inhibit NF-κB
signaling and downstream pro-inflammatory cytokines in
Citrobacter rodentium-induced colitis in mice [32,33]. In
this model, authors also found reductions in tissue neu-
trophil infiltration, corroborating our findings of lower
MPO levels (as a neutrophil marker) in intestine with
ApoE peptide treatment. In addition, IL-1 receptor an-
tagonist was found to reduce intestinal toxicity of 5-FU
in mice, suggesting that IL-1 peptides are key players in
the intestinal inflammatory response. Our findings with
NF-κB suggest that although this signaling pathway is
involved in the inflammatory response, it may be import-
ant for crypt recovery following 5-FU-induced epithelial
damage.
Our findings that ApoE deficient mice show higher
TUNEL-labeled cells, more inflammation and more
blunted villi than wild-type controls, reinforce the role of
ApoE in protecting the intestinal mucosa against 5-FU-
induce intestinal mucositis.
In our in vitro studies, however we only find improve-
ments in the number of Ki67-labeled IEC-6 cells with
ApoA-I peptide using a high treatment dose (20 μM).
However, increased cell numbers were found with COG
133, suggesting that the peptide increased cell prolifera-
tion before Ki67-stained mitoses occurred. On the other
hand, we found beneficial effects of COG 133 in lower
doses using the WST assay, a method that measures the
mithocondrial-formazan product seen in viable cells.
These differences may relate to the time periods
assessed, still under blunting mitotic effects following 5-
FU treatment [34]. In addition, WST measurements
show stronger proliferative effects of COG 133 in glu-
tamine free media (rather than standard media with
Azevedo et al. BMC Gastroenterology 2012, 12:35 Page 16 of 18
http://www.biomedcentral.com/1471-230X/12/35glutamine) in IEC-6 cells following 5-FU challenge,
suggesting that the peptide has a potential biological
effect under catabolic disease conditions when glutamine
is more likely deprived.
In order to compare the ApoE mimetic peptide effect
on cell migration and apoptosis, we also conducted
in vitro experiments with ApoA-I (D-4F), which we
found causing similar benefits to those seen with the
ApoE peptide. Thus, both may affect a common down-
stream pathway. However, both COG 133 and the D-4F
peptides are amphipathic alpha helices. Thus, the other
possibility is that they can cross plasma membranes and
enter the cell cytoplasm and have similar effects in a
receptor-independent fashion.
Noteworthy is that the intestine is a major site of action
of this peptide [35]. Recently, a novel anti-inflammatory
mechanism of ApoE-mimetic peptides was identified,
with inhibition of SET, a protein capable of increasing
endogenous PP2A phosphatase activity, which reduces
levels of phosphorilated kinase signaling and inflammatory
cytokines [36]. SET is also involved in neuronal apoptosis
due to amyloid precursors [37]. If the same mechanism is
operating in the IEC-6 cell apoptotic machinery, the inhib-
ition of SET by ApoE mimetic peptide would be anti-
apoptotic, as seen in our flow cytometry studies after 5-FU
challenge. Increased TNF-α-induced apoptosis would be
also counterbalanced by the anti-inflammatory actions of
the peptide, possibly mediated by a fine regulation of
serine-threonine kinase 1 (RIP-1) ubiquitinization and cas-
pase signaling [38]. At this point, the exact mechanism of
the anti-apoptotic property of the ApoE COG 133 remains
unclear.
In contrast to anti-proliferative findings of COG 112
and COG 133 peptides in lymphocyte cultures after
myelin oligodendrocyte glycoprotein (MOG) exposure in
a murine model of multiple sclerosis [11], our in vitro
data in crypt IEC-6 cells in addition to the observation
of improved crypt histology in treated mice suggest a
beneficial role of the peptide in improving cell viability
and crypt cell renewal following 5-FU challenge
Previous studies have shown that mucositis is not only
a manifestation of tissue change, but also with systemic
effects, with elevation of proinflammatory cytokines in
serum, such as TNF-α, IL-1β, and IL-6 of 5-FU-treated
patients, in association with the chemotherapy toxicity
without any improvements in its anti-tumor activity [39].
Colton et al. demonstrated an APOE allelic-distinct effect
on microglial nitric oxide production in the transgenic
mouse brain [40,41]. A significant increase in NO produc-
tion was found in isolated macrophages from human
APOE4 targeted transgenic mice by activation of cationic
amino acid transporters (CAT) with up-regulated innate
immune system [41]. Therefore, a possible downregulation
of CAT-1 transporters during a pro-inflammatory state ofthe intestinal mucositis would contribute to lower NO
generation and thus milder inflammatory cytokine
production.
Studies from Hoane et al. in models of brain injury
have demonstrated improvements in cognitive tests
following ApoE peptide treatment in rats. There was a
dose-dependent peptide (COG 1410) effect, with the best
dose found of 0.8 μg/kg, in studies showing recovery
following traumatic brain injury [42]. While the
mechanism of this benefit is unclear, it may involve an
anti-inflammatory effect like that which we have seen.
Conclusion
In summary, our in vivo and in vitro findings suggest
a potential protective role of the novel COG 133 pep-
tide by improving intestinal cell viability and migra-
tion, and potentially by counteracting the exacerbated
inflammatory responses following 5-FU-induced intes-
tinal mucositis.
Although our findings suggest an anti-inflammatory
action of the COG133 peptide with the involvement of the
LDL pathway, we cannot rule out nonspecific effect via a
non-LDL route. Caution is also needed regarding the ap-
plicability of our data to the clinical setting, since our study
did not evaluate anti-tumor effects of the COG133 peptide.
Further studies are needed to corroborate our findings in
order to support future clinical trials to ameliorate the side
effects of chemo/radiotherapy-associated mucositis.
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